Background and Context

The systematic exclusion of female participants from clinical research—a legacy codified in policy and reinforced by convenience—has produced a biomedical literature that is, in substantial portions, normed on male physiology. The consequences are not abstract. A 2024 call to action in women’s health research catalogues persistent barriers: underenrollment in cardiovascular trials, inadequate sex-disaggregated reporting, and funding allocations that do not track disease burden in female populations. The National Academies of Sciences, Engineering, and Medicine recently benchmarked funding against disability-adjusted life years for conditions that exclusively or predominantly affect women, finding misalignments that warrant structural correction.

Mechanisms and Physiology

Sex-based differences in drug metabolism, immune response, and disease progression are not novel observations. Cytochrome P450 isoform expression varies by sex, altering pharmacokinetics for common agents. Estrogen receptor signaling modulates inflammatory cascades and endothelial function, with implications for cardiovascular outcomes. Yet these mechanisms are rarely incorporated prospectively into trial designs. Instead, sex is treated as a covariate to be adjusted away, or worse, as a nuisance variable that justifies exclusion. The result is a literature where female-specific dose-response curves, adverse event profiles, and long-term outcomes are extrapolated from male-dominant samples—a practice that violates the principle of equipoise.

Evidence Summary

A 2018 systematic review and meta-analysis of gender differences in HIV, hepatitis B, and hepatitis C among people with severe mental illness provides a instructive case. Across 13 studies reporting sex-stratified prevalence, HIV prevalence was higher in women (8.25%; 95% CI 4.25–15.40) than in men (7.04%; 95% CI 3.75–12.82). The crude odds ratio for female sex was 1.42 (95% CI 0.96–2.10), crossing the null. The confidence interval is wide, the heterogeneity substantial, and the underlying mechanisms—higher rates of sexual violence and exploitation among women with severe mental illness—are noted but not tested. This pattern recurs across the literature: point estimates that suggest clinically meaningful differences, underpowered to achieve statistical significance, leaving practitioners without actionable guidance.

In cardiovascular medicine, a 2024 systematic review compared sex-specific outcomes for oral anticoagulants in atrial fibrillation. The standardized mean differences for bleeding and thromboembolic events between men and women were small, but the review noted that female participants were consistently underrepresented in the constituent trials, limiting precision. A 2020 meta-analysis of atrial fibrillation catheter ablation complications found that women experienced higher rates of procedural complications, with a pooled risk ratio that reached statistical significance in some but not all subgroups. The authors called for sex-stratified randomization in future trials—a recommendation that remains largely unimplemented.

Physical health disparities among sexual minority women add another layer of complexity. A 2023 comprehensive meta-analysis comparing lesbian and bisexual women to heterosexual women found elevated odds for several chronic conditions, including asthma and cardiovascular disease. Effect sizes were generally modest (odds ratios in the 1.2–1.5 range) and confidence intervals often included unity after adjustment for confounders. The authors highlight that minority stress pathways—chronic discrimination, healthcare avoidance, and elevated allostatic load—are plausible mediators, but longitudinal data are sparse. Without prospective cohort studies that oversample sexual minority women, causal inference remains speculative.

Practical Application

For the clinician, these findings underscore the importance of individualized risk assessment that accounts for sex and, where data exist, sexual orientation. When prescribing anticoagulants to women with atrial fibrillation, current evidence does not support a blanket preference for one agent over another, but it does warrant heightened vigilance for bleeding—particularly in older women with low body weight. For women with severe mental illness, HIV screening protocols should be optimized, recognizing that prevalence estimates in this subgroup exceed general population rates by an order of magnitude. For sexual minority women, cardiovascular risk factor management should be proactive, not reactive, acknowledging that traditional risk calculators may underestimate true risk due to unmeasured psychosocial variables.

Caveats and Limitations

The evidence base remains fragmented. Many meta-analyses pool studies with heterogeneous inclusion criteria, outcome definitions, and adjustment strategies. Publication bias is a concern; null findings on sex differences are less likely to be submitted or accepted. Moreover, the binary operationalization of sex in most research obscures the experiences of intersex and transgender individuals, a limitation that the field is only beginning to address. The call for female-specific research should not be misread as a call for exclusion of male participants, but rather for deliberate, adequately powered, sex-stratified designs that can detect interaction effects. Until such designs become the norm, clinical recommendations will continue to rest on shaky foundations.

Readers with personal medical concerns should consult a physician or healthcare professional for individualized guidance.